CLAIMS

1. A dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size, wherein said liquid comprises between about 0.3 mg and about 0.9 mg of a siNA comprising SEQ ID NO. 3 and optionally one or more pharmaceutically acceptable diluents and optionally one or more excipients.

2. A dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size, wherein said liquid comprises between about 0.3 mg and about 0.9 mg of a siRNA comprising SEQ ID NO: 2 in a solution comprising phosphate-buffered saline at a concentration of between about 7.5 mg/ml and about 22.5 mg/ml.

3. A kit comprising:

(a) a dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size; and

(b) written instructions specifying that between about 0.3 mg and about 0.9 mg of an siNA comprising SEQ ID NO: 1 in the form of one droplet is to be applied to each eye.

4. A kit comprising:

(a) a dispenser for dispensing a pharmaceutical dosage in liquid form, said dispenser comprising a container for holding a charge of said liquid and an orifice for dispensing a droplet of said liquid of predetermined size; and

(b) written instructions specifying that between about 0.3 mg and about 0.9 mg of a siRNA comprising SEQ ID NO: 2 in a final concentration of between about

7.5 mg/ml and about 22.5 mg/ml in PBS in the form of one droplet is to be applied to each eye.

5. The use of a short interfering nucleic acid molecule (siNA) comprising the nucleotide sequence of SEQ ID NO: 3 in the manufacture of a medicament for the treatment of an eye disorder characterized by increased intraocular pressure (IOP) wherein said si~~R~~NA is topically administered to the corneal surface of the eye of a patient in need thereof at a dose of between about 0.3 mg and about 0.9 mg.

6. Use of between about 0.3 mg and 0.9 mg of a siRNA comprising SEQ ID NO: 2 in phosphate buffered saline (PBS) in the manufacture of a medicament for the treatment of an eye disorder characterized by increased intraocular pressure (IOP) wherein said medicament is topically administered to the corneal surface of the eye of a patient in need thereof.

7. Use of claim 5, wherein the siNA is administered once per day.

8. Use of claim 5, wherein the siNA is delivered in a volume of between about 30 µl and about 40 µl.

9. Use of claim 5, wherein the siNA is delivered to the eye with an eyedropper.

~~10. Use of claim 5, wherein the IOP of the patient is reduced by between about 25% and about 30% compared with the IOP of the patient prior to the administration of the siNA.~~

~~11. Use of claim 5, wherein the siNA provides a sustained decrease in IOP that lasts for longer than 24 hours after administration of the siNA.~~

~~12. Use of claim 5, wherein the decrease in IOP is present for at least 8 hours.~~

~~13. Use of claim 5, wherein decreased IOP persists for at least 2 days.~~

~~14~~10. Use of claim 5, wherein the siNA is short interfering ribonucleic acid (siRNA).

~~15~~11. Use of claim ~~14~~10, wherein the siRNA is double stranded RNA (dsRNA).

~~16~~12. Use of claim ~~14~~10, wherein the siRNA is short hairpin RNA (shRNA).

~~17~~13. Use of claim 5, wherein the siNA comprises at least one modified oligonucleotide.

~~18~~14. Use of claim 5, wherein the siNA comprises at least one linkage between two nucleotides that is not a phosphodiester linkage.

~~19~~15. Use of claim 5, wherein the eye disorder is selected from the group consisting of open angle glaucoma, angle closure glaucoma, and congenital glaucoma.

~~20~~16. Use of claim 5, wherein the siNA is 40 nucleotides or fewer.

~~21~~17. Use of claim ~~14~~10, wherein the siRNA is hybridised to its complement to make a dsRNA.

~~22~~18. Use of claim ~~15~~11, wherein the dsRNA has a dinucleotide 3' overhang.

~~23~~19. Use of claim ~~22~~18, wherein the dinucleotide 3' overhang is made of thymidine nucleotides.

~~24~~20. Use of claim 5, wherein more than one type of siNA is administered to the patient.

~~25~~21. Use of claim ~~24~~20, wherein the more than one type of siNA decreases or inhibits the expression of the same gene.

~~26~~22. Use of claim 5, wherein said siNA is unmodified.